These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 16455306)

  • 21. What is Zelen's design?
    Torgerson DJ; Roland M
    BMJ; 1998 Feb; 316(7131):606. PubMed ID: 9518917
    [No Abstract]   [Full Text] [Related]  

  • 22. Using scratch card technology for random allocation concealment in a clinical trial with a crossover design.
    Beksinska ME; Joanis C; Smit JA; Pienaar J; Piaggio G
    Clin Trials; 2013 Feb; 10(1):125-30. PubMed ID: 23188890
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantification methods were developed for selection bias by predictability of allocations with unequal block randomization.
    Dupin-Spriet T; Fermanian J; Spriet A
    J Clin Epidemiol; 2005 Dec; 58(12):1269-76. PubMed ID: 16291471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The use of unequal randomisation in clinical trials--An update.
    Peckham E; Brabyn S; Cook L; Devlin T; Dumville J; Torgerson DJ
    Contemp Clin Trials; 2015 Nov; 45(Pt A):113-22. PubMed ID: 26027788
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised consent designs in cancer clinical trials.
    Altman DG; Whitehead J; Parmar MK; Stenning SP; Fayers PM; Machin D
    Eur J Cancer; 1995 Nov; 31A(12):1934-44. PubMed ID: 8562145
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Designing medical and educational intervention studies. A review of some alternatives to conventional randomized controlled trials.
    Bradley C
    Diabetes Care; 1993 Feb; 16(2):509-18. PubMed ID: 8432226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bias in randomised controlled trials: comparison of crossover group and parallel group designs.
    Sedgwick P
    BMJ; 2015 Aug; 351():h4283. PubMed ID: 26253465
    [No Abstract]   [Full Text] [Related]  

  • 28. Use of pre-enrollment randomization and delayed consent to maximize participation in a clinical trial of opt-in versus opt-out tobacco treatment.
    Faseru B; Mussulman LM; Nazir N; Ellerbeck EF; Shergina E; Scheuermann TS; Gajewski BJ; Catley D; Richter KP
    Subst Abus; 2022; 43(1):1035-1042. PubMed ID: 35435813
    [No Abstract]   [Full Text] [Related]  

  • 29. Randomized consent designs for clinical trials: an update.
    Lin CD; Lui KJ
    Stat Med; 2002 Sep; 21(17):2601-3; author reply 2603-5. PubMed ID: 12205700
    [No Abstract]   [Full Text] [Related]  

  • 30. A flexible random allocation program for multi-institutional clinical trials.
    Odaka T; Akazawa K; Watanabe Y; Nose Y; Ogura H
    J Med Syst; 1994 Feb; 18(1):39-53. PubMed ID: 8064207
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Zelen design may be the best choice for a heroin-provision experiment.
    Schellings R; Kessels AG; ter Riet G; Sturmans F
    J Clin Epidemiol; 1999 Jun; 52(6):503-7. PubMed ID: 10408988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An easily customized, random allocation system using the minimization method for multi-institutional clinical trials.
    Kenjo Y; Antoku Y; Akazawa K; Hanada E; Kinukawa N; Nose Y
    Comput Methods Programs Biomed; 2000 May; 62(1):45-9. PubMed ID: 10699684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recruitment of ethnic minorities to asthma studies.
    van der Wouden JC
    Thorax; 2005 Mar; 60(3):257; author reply 257. PubMed ID: 15741450
    [No Abstract]   [Full Text] [Related]  

  • 34. On the mathematical basis of Zelen's prerandomized designs.
    Brunner E; Neumann N
    Methods Inf Med; 1985 Jul; 24(3):120-30. PubMed ID: 4033442
    [No Abstract]   [Full Text] [Related]  

  • 35. Patient registration and treatment allocation in multicenter clinical trials using a FAX-OCR system.
    Akazawa K; Kamakura T; Sakamoto M; Odaka T; Nose Y
    Methods Inf Med; 1994 Dec; 33(5):530-4. PubMed ID: 7869952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sensitivity analysis of causal inference in a clinical trial subject to crossover.
    Xie H; Heitjan DF
    Clin Trials; 2004 Feb; 1(1):21-30. PubMed ID: 16281459
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crossover is not associated with faster trial accrual.
    Chen EY; Prasad V
    Ann Oncol; 2018 Mar; 29(3):776-777. PubMed ID: 29267893
    [No Abstract]   [Full Text] [Related]  

  • 38. Response to Hadorn et al on increasing recruitment into randomised clinical trials.
    Paul C; Moore A
    N Z Med J; 2013 Sep; 126(1383):104-6. PubMed ID: 24158002
    [No Abstract]   [Full Text] [Related]  

  • 39. Randomised controlled trials: "within subject" versus "between subject" designs.
    Sedgwick P
    BMJ; 2014 Oct; 349():g6435. PubMed ID: 25954990
    [No Abstract]   [Full Text] [Related]  

  • 40. Formula predicting survival in patients with acute myelogenous leukemia.
    Chung SJ
    Int J Biomed Comput; 1991 Dec; 29(3-4):283-93. PubMed ID: 1778643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.